KL-6: A serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis

Journal of Internal Medicine

Volumn 271, Issue 6, 2012, Pages 589-597

  Fathi, M ^a   Barbasso Helmers, S ^a,b   Lundberg, I E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dermatomyositis; Interstitial lung disease; KL 6; Polymyositis

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; PROTEIN KL 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; ENZYME IMMUNOASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; LUNG VENTILATION; MALE; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESIDUAL VOLUME; SENSITIVITY AND SPECIFICITY; TOTAL LUNG CAPACITY; VITAL CAPACITY;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCIN-1; POLYMYOSITIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84861233536     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02459.x     Document Type: Article

References (31)

1. Fathi M, Vikgren J, Boijsen M et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59: 677-85.
2. Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984; 14: 60-76.
3. Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 1974; 65: 403-7.
4. Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings. Arch Intern Med 1981; 141: 1005-10.
5. Tazelaar HD, Viggiano RW, Pickersgill J et al. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141: 727-33.
6. Marie I, Lahaxe L, Benveniste O et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010; 162: 337-44.
7. Benbassat J, Gefel D, Larholt K et al. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985; 28: 249-55.
8. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25: 234-9.
9. Dankó K, Ponyi A, Constantin T et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004; 83: 35-42.
10. Torres C, Belmonte R, Carmona L et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006; 39: 205-15.
11. Bronner IM, van der Meulen MF, de Visser M et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006; 65: 1456-61.
12. Kobayashi I, Ono S, Kawamura N et al. KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis. J Pediatr 2001; 138: 274-6.
13. Janssen R, Sato H, Grutters JC et al. Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest 2003; 124: 2119-25.
14. Kinoshita F, Hamano H, Harada H et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 2004; 98: 1131-7.
15. Yanaba K, Hasegawa M, Hamaguchi Y et al. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003; 21: 429-36.
16. Bandoh S, Fujita J, Ohtsuki Y et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis 2000; 59: 257-62.
17. Kubo M, Ihn H, Yamane K et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford) 2000; 39: 632-6.
18. Kumánovics G, Minier T, Radics J et al. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008; 26: 414-20.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
20. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
21. Griggs RC, Askanas V, DiMauro S et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-13.
22. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-64.
23. Inoue Y, Nishimura K, Shiode M et al. Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Tuber Lung Dis 1995; 76: 230-329.
24. Hamada H, Kohno N, Yokoyama A et al. KL-6 as a serologic indicator of Pneumocystis carinii pneumonia in immunocompromised hosts. Intern Med 1998; 37: 307-10.
25. Kida Y, Maeshima E, Furukawa K et al. A case of polymyositis with a significantly high level of KL-6 associated with pancreatic cancer. Mod Rheumatol 2007; 17: 262-4.
26. Ogawa Y, Ishikawa T, Ikeda K et al. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res 2000; 6: 4069-72.
27. Osaka A, Yanagihara K, Yamada Y et al. Elevation of serum KL-6 glycoprotein or surfactant protein-D in adult T-cell leukemia with distinct pulmonary complications. Tohoku J Exp Med 2009; 218: 99-105.
28. Kohna N, Inoue Y, Hamada H et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer SUPPL 1994; 8: 81-3.
29. Hamada H, Kohno N, Akiyama M et al. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest 1992; 101: 858-60.
30. Fukaya S, Oshima H, Kato K et al. KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases. Rheumatol Int 2000; 19: 223-5.
31. Funauchi M, Shimadsu H, Tamaki C et al. Role of endothelial damage in the pathogenesis of interstitial pneumonitis in patients with polymyositis and dermatomyositis. J Rheumatol 2006; 33: 903-6.